GeneOne Life Science resumes operations at US Plant 1, begins producing existing orders early next month
Predicted impact: Medium
US plant restart and early-month orders are meaningful for a small biotech; $106.5B won damages noted separately.
GeneOne Life Science진원생명과학
011000 · KOSPI · ₩011000 · 진원생명과학
₩2,670 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −75.78%
- Market cap
- ₩49B
- Enterprise value
- ₩50B
- P/E
- —
- P/B
- 1.4×
- Dividend yield
- 0.0%
- ROE
- −137.1%
- Net margin
- −395.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−78.6% from the high
₩2,600Today: ₩2,670 – ₩2,670₩12,450
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M−41.7%
- YTD−72.7%
- 1Y−75.8%
- Volume today
- —
- Traded today
- —
- Listed shares
- 18,176,581
- EPS (12 months)
- −₩2,692
- Earnings yield −100.8%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Plant restart and existing orders resuming is a mildly positive operational update. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat0% over the last month; the price is below its 20-day average.
- News impactHigh8 news items and filings in two weeks; 1 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
GeneOne Life Science stock overview
GeneOne Life Science (진원생명과학, KRX: 011000) is listed on KOSPI, in the Biotech & Pharma sector. GeneOne Life Science (Genexine-related DNA vaccine developer) operates a biopharmaceutical business through two segments: a contract development and manufacturing organization (CDMO) for plasmid DNA products used in gene therapies and DNA vaccines, and the development of next-generation nucleic acid-based biopharmaceuticals and anti-inflammatory drugs. Its shares closed at ₩2,670 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩49B.
Key facts
- Market cap
- ₩49B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- GeneOne Life Science (Genexine-related DNA vaccine developer) operates a biopharmaceutical business through two segments: a contract development and manufacturing organization (CDMO) for plasmid DNA products used in gene therapies and DNA vaccines, and the development of next-generation nucleic acid-based biopharmaceuticals and anti-inflammatory drugs.
Quick answers about GeneOne Life Science
- What does GeneOne Life Science do?
- GeneOne Life Science (Genexine-related DNA vaccine developer) operates a biopharmaceutical business through two segments: a contract development and manufacturing organization (CDMO) for plasmid DNA products used in gene therapies and DNA vaccines, and the development of next-generation nucleic acid-based biopharmaceuticals and anti-inflammatory drugs. S. , which also supplies mRNA production services, and it sells through VGXI USA.
- What is the market cap of GeneOne Life Science?
- The market capitalisation of GeneOne Life Science was ₩49B at the close on Oct 27, 2026.
- Who are the largest shareholders of GeneOne Life Science?
- According to the latest official filings, the largest reported holders are Donbanseong Investment Partnership No. 1 (12.42%, as of Jun 29, 2026); Park Young-geun (4.87%, as of Feb 13, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.55%, as of Jul 31, 2026).
- When is the next earnings report from GeneOne Life Science?
- Korean companies rarely announce results dates in advance. Based on when GeneOne Life Science filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own GeneOne Life Science?
- Yes. The National Pension Service held 0.19% of GeneOne Life Science shares as of Dec 31, 2025.
Company profile
GeneOne Life Science (Genexine-related DNA vaccine developer) operates a biopharmaceutical business through two segments: a contract development and manufacturing organization (CDMO) for plasmid DNA products used in gene therapies and DNA vaccines, and the development of next-generation nucleic acid-based biopharmaceuticals and anti-inflammatory drugs. Its CDMO unit is run through its U.S. subsidiary VGXI, Inc., which also supplies mRNA production services, and it sells through VGXI USA. Its drug development pipeline includes DNA vaccines for MERS, Zika, SFTS and COVID-19, with several programs conducted with partners such as INOVIO and KAIST.
Written by AI from the company's latest annual report.
- Korean name
- 진원생명과학
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김경진(단독대표)
- Founded
- Jan 1976
- Listed
- Nov 1987
- Listed shares
- 18,176,581
- Fiscal year ends
- Month 12
- Website
- www.genels.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Jinwon Lifescience to Pay ₩106.5B in Damages Under Court Ruling in US Lawsuit with Innovio
High impactPredicted impact: High
US ruling to pay ₩106.5B damages, about 220% of market value and 8x revenue.
Recent filings
See all- Other management mattersOct 23, 2026
- Amended: Rights offering (paid-in capital increase) decisionOct 23, 2026
- Lawsuit filed or ruledOct 21, 2026
- Amended: Rights offering (paid-in capital increase) decisionOct 15, 2026
- [Amended] Notice of Shareholder Register Closure Period or Record Date SettingOct 14, 2026
Titles in Korean until English translations are added.
Also known as: GeneOne Life Science / 진원생명과학 / 011000 / KRX:011000
Source: KRX statistical information